Bristol-Myers Squibb has announced a new clinical research collaboration with Janssen Biotech to evaluate Bristol-Myers Squibb’s immuno-oncology agent Opdivo (nivolumab) and Janssen’s Listerial monocytogenes cancer immunotherapy.

Opdivo is a human antibody designed to alleviate immune suppression. The Janssen therapy is designed to induce the local recruitment and activation of innate and adaptive effector cells and expansion of mesothelin-specific T cells.

The Phase 2 clinical trial will evaluate the tolerability and clinical activity of the combination of these agents in patients with non-small cell lung cancer.